UKUK

Oxford BioMedica partners with ImaginAB in antibody research

08.06.2011

Oxford – Oxford BioMedica plc joins forces with ImaginAb, Inc, a specialist in the development of engineered antibody fragments for diagnostic imaging. Under the terms of a research agreement announced yesterday, the US firm will engineer a companion PET and SPECT imaging agent based on an antibody that targets Oxford Biomedica’s proprietary 5T4 tumour antigen and is intended to be used to diagnose ovarian cancer.
With TroVax, Oxford BioMedica has a 5T4-specific therapeutic vaccine candidate in Phase II development. Furthermore, the gene therapy specialist is in preclinical co-development of a 5T4-targeted antibody therapy with Pfizer. The 5T4 tumour antigen is a unique protein found on most common types of solid cancer. It is a potential target for novel anti-cancer interventions given its restricted expression in normal tissues and its high prevalence on the surface of both primary and metastatic cancerous cells.
Following proof-of-concept, the agreement of Oxford Biomedica with ImaginAb includes an option for the US firm to negotiate an exclusive license for commercialisation of a an 4T5-antibody-based imaging diagnostic. Oxford BioMedica could receive proceeds of up to US$4 million as well as royalties on product sales. Just last month the British firm expanded its existing 5T4 antibody therapeutics collaboration with Pfizer to include diagnostic use of 5T4 antibodies The amended deal grants Pfizer non-exclusive rights for the diagnostic use of 5T4 antibodies and includes an option for commercialisation of a 5T4-based diagnostic.

UKUK

02.04.2012

London - The not-for-profit UK Biobank, the most comprehensive health study in Britain, is now accessible to researchers from industry and academia. The resource, which contains some 1,000 pieces of health and lifestyle...

UKUK

21.03.2012

London – The British Wellcome Trust announced on 20 March that it will launch a £200m business to invest directly in healthcare and life sciences companies. The business, up to now running under its working title Project Sigma,...

UKUK

07.03.2012

Nanopore sequencer Oxford Nanopore Technologies, a UK firm that promises its third-generation technology could theoretically sequence a human genome in 15 minutes, impressed scientists with the first public presentation of its...

UKUK

06.03.2012

GlaxoSmithKline (GSK) is further strengthening its activity in the area of rare diseases. The London-based pharma giant has signed an early-stage deal to develop and commercialise treatments for lysosomal storage disorders...

UKUK

27.02.2012

London/Montreal - Angiochem will collaborate with British pharma trust GlaxoSmithKline (GSK) plc on treatments for lysosomal storage diseases (LSD). London-based GSK will pay $300m, including up to $31.5m in upfront cash and...

UKUK

08.02.2012

London - GlaxoSmithKline re-adjusts its €3.7bn R&D budget. Following a review, three of 38 R&D units will be cut and four new ones installed, the UK drug company said in a statement on 7 Februray. Furthermore, six of the...

UKUK

03.02.2012

London - AstraZeneca tries to shed some weight, anticipating a tough year ahead. 7,300 jobs will be gone soon, the Anglo-Swedish drug company said in a statement. Research and development operations will be cancelled in...

UKUK

16.01.2012

Newhouse – An example of Schumpeter's dictum of creative destruction can be witnessed in Scotland. A former research site of US-pharma company Merck will be reborn as a biotech science park. BioCity Scotland Ltd, a joint venture...

Displaying results 1 to 10 out of 396

1-10 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/news/messages-archive/archive-uk/article/oxford-biomedica-partners-with-imaginab-in-antibody-research.html

Print Magazine

Product of the week

Products

Events

All Events

Stock list

All quotes

TOP

    FLOP

      TOP

        FLOP

          TOP

            FLOP

              No liability assumed, Date: 26.11.2014

              Current issue

              All issues